In a landmark achievement for international public health, the World Health Organization (WHO) has officially validated El Salvador as having eliminated trachoma as a public health problem. Trachoma, an infectious disease caused by the bacterium Chlamydia trachomatis, has historically stood as the world’s leading infectious cause of blindness. This validation marks a significant victory for the Central American nation and serves as a beacon of progress for the global effort to eradicate neglected tropical diseases (NTDs) by 2030.
El Salvador now holds the distinction of being the first country in Central America—and only the second in the Americas, following Mexico—to reach this monumental health milestone. The achievement places the nation among an elite group of 64 countries worldwide that have been recognized by the WHO for successfully eliminating at least one neglected tropical disease.
The Nature of the Threat: Understanding Trachoma
Trachoma is a chronic, debilitating condition that thrives in environments characterized by limited access to clean water, sanitation, and hygiene (WASH). The disease is transmitted through contact with infectious eye and nasal discharge, often spread by direct contact, shared towels, or flies.
The cycle of infection is insidious. Repeated episodes of the disease lead to chronic inflammation of the inner eyelid. Over time, this causes the eyelid to scar and turn inward—a condition known as trichiasis. In this advanced stage, the eyelashes scrape against the cornea, causing excruciating pain, permanent scarring, and eventually, irreversible blindness. Because it disproportionately affects the world’s most impoverished and marginalized communities, trachoma is classified as a neglected tropical disease, often trapping families in a cycle of physical suffering and economic hardship.
A Chronology of Elimination: The Path to Success
The path to validation was neither brief nor simple. It required a rigorous, multi-year epidemiological review to ensure that the disease was truly absent and that the country possessed the structural capacity to prevent its re-emergence.
2023–2026: The Assessment Phase
Beginning in 2023, the Salvadoran government, in partnership with the Pan American Health Organization (PAHO), launched a series of targeted assessments. These were not generic health checks; they were high-precision surveys focused on communities previously identified as having social or environmental risk factors that could harbor the bacteria.
Health teams fanned out across the country, specifically targeting children aged 1–9 to identify active inflammatory signs, and adults to check for signs of trichiasis. By 2026, the data was conclusive: there was no evidence of active transmission, no detected cases of active trachoma in children, and no evidence of advanced, blinding cases in the adult population.
The Criteria for Success
To receive WHO validation, a country must meet strict scientific benchmarks:
- Low Prevalence: A prevalence of trachomatous trichiasis (TT) "unknown to the health system" of less than 0.2% among those aged 15 and older.
- Pediatric Health: A prevalence of trachomatous inflammation (follicular) in children aged 1–9 of less than 5% in every formerly endemic district.
- Surveillance Capacity: Evidence of a functioning health system capable of identifying and managing any future "incident" cases of trichiasis.
El Salvador met these rigorous standards, confirming that the disease no longer constitutes a public health threat within its borders.
A Multisectoral Strategy
The success in El Salvador was not the result of a single medical intervention but rather a comprehensive, multisectoral approach. The government understood that defeating a disease rooted in poverty required more than just antibiotics; it required systemic change.
Integrated Health Services
The Ministry of Health strengthened primary healthcare services, ensuring that eye health screenings were integrated into routine medical care. By training local health personnel to identify the early signs of trichiasis, the country ensured that even if a rare case were to emerge, it could be treated before causing permanent vision loss.
Infrastructure and Hygiene
Recognizing that trachoma is a disease of environmental inequity, the country prioritized improvements in water, sanitation, and hygiene (WASH) infrastructure. By providing cleaner water and sanitation facilities to vulnerable populations, the country effectively cut off the transmission routes of the Chlamydia trachomatis bacterium.
Collaborative Governance
The effort was bolstered by the "Initiative for the Elimination of Trachoma in the Americas," a PAHO-led program supported significantly by the Government of Canada. This international collaboration provided the necessary technical and financial resources to sustain the screening efforts, allowing El Salvador to reach the most remote and marginalized populations effectively.
Official Responses: Celebrating the Milestone
The international health community has hailed El Salvador’s success as a template for other nations struggling with similar burdens.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, offered his personal commendation: "I congratulate El Salvador on this remarkable achievement. It is a testament to the power of political commitment, strategic investment, and community engagement. El Salvador’s success is a vital step towards our global target of eliminating trachoma worldwide by 2030 and a clear signal that a healthier, more equitable future is within reach."
Dr. Jarbas Barbosa, Director of PAHO, emphasized the human element of the victory: "This validation reflects El Salvador’s commitment to reaching populations in the most vulnerable conditions. It is the result of sustained efforts to reach communities, identify potential cases, and ensure no one was left behind."
El Salvador’s Minister of Health, Francisco Alabi, expressed national pride in the speed of the progress: "We are proud to have reached this achievement in just three years, positioning the country in the region and improving the visual health of our population."
Implications for the Americas and the World
The implications of this validation extend far beyond El Salvador. In the Americas, trachoma remains a public health challenge in rural and remote regions of Brazil, Colombia, Guatemala, and Peru. Furthermore, several other nations—including Bolivia, Ecuador, Guyana, Panama, Paraguay, and Venezuela—are currently expanding their epidemiological surveillance to determine the status of the disease.
El Salvador’s success provides a "proof of concept" that rapid elimination is possible when high-level political will meets sustained public health investment. It validates the PAHO Disease Elimination Initiative, which targets more than 30 communicable diseases for eradication in the Americas by 2030.
Sustaining the Achievement
The WHO has issued a clear directive to El Salvador: the work is not over. To prevent the re-emergence of the disease, the country must maintain its robust surveillance systems. The infrastructure built during the elimination phase—trained personnel, integrated reporting systems, and improved WASH access—must be treated as a permanent feature of the national health system rather than a temporary program.
Conclusion: A Road Map for the Future
The elimination of trachoma in El Salvador serves as a milestone in the broader "Road Map for Neglected Tropical Diseases 2021–2030." By demonstrating that a country can move from being an endemic territory to a validated, disease-free nation in a remarkably short window, El Salvador has provided the global health community with a renewed sense of optimism.
As the world looks toward 2030, the lesson from San Salvador is clear: when governments commit to equity, invest in basic infrastructure, and foster deep community engagement, the most stubborn diseases of poverty can be consigned to the history books. For the people of El Salvador, the future is now significantly brighter, as the fear of a preventable, blinding disease has been successfully removed from their public health landscape.
About the Author
